Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Matthew Ingham
Alliance for Clinical Trials in Oncology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
145 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centro Comprensivo de Cancer de Upr
San Juan, Puerto Rico
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Alaska Women'S Cancer Care
Anchorage, Alaska, United States
- Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Epic Care-Dublin
Dublin, California, United States
- Epic Care Partners in Cancer Care
Emeryville, California, United States
- City of Hope at Irvine Lennar
Irvine, California, United States
- Contra Costa Regional Medical Center
Martinez, California, United States
- Epic Care Cyberknife Center
Walnut Creek, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Memorial Hospital North
Colorado Springs, Colorado, United States
- Uchealth Memorial Hospital Central
Colorado Springs, Colorado, United States
- Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado, United States
- Poudre Valley Hospital
Fort Collins, Colorado, United States
- Uchealth Greeley Hospital
Greeley, Colorado, United States
- Medical Center of the Rockies
Loveland, Colorado, United States
- Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut, United States
- Smilow Cancer Hospital Care Center at Glastonbury
Glastonbury, Connecticut, United States
- Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut, United States
- Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut, United States
- Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, United States
- Yale University
New Haven, Connecticut, United States
- Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut, United States
- Smilow Cancer Hospital Care Center at Long Ridge
Stamford, Connecticut, United States
- Smilow Cancer Hospital-Torrington Care Center
Torrington, Connecticut, United States
- Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut, United States
- Smilow Cancer Hospital-Waterbury Care Center
Waterbury, Connecticut, United States
- Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut, United States
- Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States
- Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
- Lewis Cancer and Research Pavilion at Saint Joseph'S/candler
Savannah, Georgia, United States
- Saint Luke'S Cancer Institute - Boise
Boise, Idaho, United States
- Saint Luke'S Cancer Institute - Fruitland
Fruitland, Idaho, United States
- Saint Luke'S Cancer Institute - Meridian
Meridian, Idaho, United States
- Saint Luke'S Cancer Institute - Nampa
Nampa, Idaho, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Mar 2023
- Primary completion
- 13 Aug 2024
- Completion
- 30 Jan 2027
- Last update posted
- 1 Jun 2026
- Registered enrollment
- 74
- Registry id
- NCT05432791
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.